疾病生物标志物的机遇与挑战：《转化医学杂志》新增版块。
Opportunities and challenges of disease biomarkers: a new section in the Journal of Translational Medicine.
机构信息
Department of Respiratory Medicine, Biomedical Research Center, Zhongshan Hospital Qing-Pu Branch, Fudan University, Shanghai, China.
出版信息
J Transl Med. 2012 Dec 5;10:240. doi: 10.1186/1479-5876-10-240.
Abstract
Disease biomarkers are defined to diagnose various phases of diseases, monitor severities of diseases and responses to therapies, or predict prognosis of patients. Disease-specific biomarkers should benefit drug discovery and development, integrate multidisciplinary sciences, be validated by molecular imaging. The opportunities and challenges in biomarker development are emphasized and considered. The Journal of Translational Medicine opens a new Section of Disease Biomarkers to bridge identification and validation of gene or protein-based biomarkers, network biomarkers, dynamic network biomarkers in human diseases, patient phenotypes, and clinical applications. Disease biomarkers are also important for determining drug effects, target specificities and binding, dynamic metabolism and pharmacological kinetics, or toxicity profiles.
摘要
疾病生物标志物被定义为用于诊断疾病的各个阶段、监测疾病的严重程度和对治疗的反应，或预测患者的预后。疾病特异性生物标志物应有利于药物发现和开发，整合多学科科学，并通过分子成像进行验证。强调并考虑了生物标志物开发中的机遇和挑战。《转化医学杂志》开辟了一个新的疾病生物标志物版块，旨在连接基因或蛋白质生物标志物、网络生物标志物、人类疾病中的动态网络生物标志物、患者表型以及临床应用的鉴定和验证。疾病生物标志物对于确定药物作用、靶标特异性和结合、动态代谢和药代动力学或毒性特征也很重要。
相似文献
1
Opportunities and challenges of disease biomarkers: a new section in the Journal of Translational Medicine.疾病生物标志物的机遇与挑战：《转化医学杂志》新增版块。
J Transl Med. 2012 Dec 5;10:240. doi: 10.1186/1479-5876-10-240.
2
Opportunities and challenges of disease biomarkers: a new section in the Journal of Translational Medicine.疾病生物标志物的机遇与挑战：《转化医学杂志》新设栏目
J Transl Med. 2012 Nov 7;10:220. doi: 10.1186/1479-5876-10-220.
3
Translational biomarkers: from discovery and development to clinical practice.转化生物标志物：从发现与开发到临床应用
Drug Discov Today Technol. 2016 Sep-Dec;21-22:3-10. doi: 10.1016/j.ddtec.2016.10.001. Epub 2016 Nov 19.
4
Assessment of translational risk in drug research: Role of biomarker classification and mechanism-based PKPD concepts.药物研究中翻译风险的评估：生物标志物分类和基于机制的 PKPD 概念的作用。
Eur J Pharm Sci. 2017 Nov 15;109S:S72-S77. doi: 10.1016/j.ejps.2017.08.006. Epub 2017 Aug 13.
5
Translational medicine--a paradigm shift in modern drug discovery and development: the role of biomarkers.转化医学——现代药物发现和开发的范式转变：生物标志物的作用。
Adv Exp Med Biol. 2009;655:1-12. doi: 10.1007/978-1-4419-1132-2_1.
6
Isotopic biomarker discovery and application in translational medicine.同位素生物标志物的发现及其在转化医学中的应用。
Drug Discov Today. 2010 Feb;15(3-4):127-36. doi: 10.1016/j.drudis.2009.12.005. Epub 2009 Dec 28.
7
Introducing the cancer microenvironment section of Journal of Translational Medicine.介绍《转化医学杂志》的癌症微环境板块。
J Transl Med. 2010 Jun 22;8:60. doi: 10.1186/1479-5876-8-60.
8
Safety biomarkers in preclinical development: translational potential.临床前开发中的安全性生物标志物：转化潜力。
Vet Pathol. 2014 Jan;51(1):281-91. doi: 10.1177/0300985813505117. Epub 2013 Oct 3.
9
Introducing the nutrition & metabolism section of Journal of Translational Medicine.介绍《转化医学杂志》的营养与代谢板块。
J Transl Med. 2012 Jan 30;10:17. doi: 10.1186/1479-5876-10-17.
10
Biomarkers, Translational Medicine, and Drug Development: An Interview with Chirag R. Parikh, MD, PhD.生物标志物、转化医学与药物研发：对医学博士、哲学博士奇拉格·R·帕里克的访谈
Yale J Biol Med. 2017 Mar 29;90(1):153-156. eCollection 2017 Mar.
引用本文的文献
1
Plasma proteomics in pediatric patients with sepsis- hopes and challenges.脓毒症患儿的血浆蛋白质组学——希望与挑战
Clin Proteomics. 2025 Mar 18;22(1):10. doi: 10.1186/s12014-025-09533-9.
2
Role of ferroptosis in colorectal cancer.铁死亡在结直肠癌中的作用。
World J Gastrointest Oncol. 2023 Feb 15;15(2):225-239. doi: 10.4251/wjgo.v15.i2.225.
3
Bioactive substances inhibiting COX-2 and cancer cells isolated from the fibrous roots of (Lour.) Harms.从（劳尔）哈姆斯须根中分离出的抑制COX-2和癌细胞的生物活性物质。
RSC Adv. 2023 Jan 26;13(5):3346-3363. doi: 10.1039/d2ra06931h. eCollection 2023 Jan 18.
4
Immunization Combined with Ferroptosis Related Genes to Construct a New Prognostic Model for Head and Neck Squamous Cell Carcinoma.免疫与铁死亡相关基因联合构建头颈部鳞状细胞癌新的预后模型
Cancers (Basel). 2022 Aug 24;14(17):4099. doi: 10.3390/cancers14174099.
5
Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognostic Model for Colon Cancer.鉴定和验证与铁死亡相关的 lncRNA 特征作为结肠癌的一种新的预后模型。
Front Immunol. 2022 Jan 26;12:783362. doi: 10.3389/fimmu.2021.783362. eCollection 2021.
6
An Original Ferroptosis-Related Gene Signature Effectively Predicts the Prognosis and Clinical Status for Colorectal Cancer Patients.一种原始的铁死亡相关基因特征可有效预测结直肠癌患者的预后和临床状况。
Front Oncol. 2021 Jun 24;11:711776. doi: 10.3389/fonc.2021.711776. eCollection 2021.
7
Dried Blood Spot (DBS) Methodology Study for Biomarker Discovery in Lysosomal Storage Disease (LSD).用于溶酶体贮积症（LSD）生物标志物发现的干血斑（DBS）方法学研究
Metabolites. 2021 Jun 13;11(6):382. doi: 10.3390/metabo11060382.
8
Identification of Early Warning Signals at the Critical Transition Point of Colorectal Cancer Based on Dynamic Network Analysis.基于动态网络分析的结直肠癌关键转变点早期预警信号识别
Front Bioeng Biotechnol. 2020 May 29;8:530. doi: 10.3389/fbioe.2020.00530. eCollection 2020.
9
Can glypican-3 be a disease-specific biomarker?磷脂酰肌醇蛋白聚糖-3能否成为疾病特异性生物标志物？
Clin Transl Med. 2017 Dec;6(1):18. doi: 10.1186/s40169-017-0146-5. Epub 2017 May 16.
10
Network biomarkers, interaction networks and dynamical network biomarkers in respiratory diseases.呼吸系统疾病的网络生物标志物、相互作用网络和动态网络生物标志物。
Clin Transl Med. 2014 Jun 24;3:16. doi: 10.1186/2001-1326-3-16. eCollection 2014.
本文引用的文献
1
Understanding drug uptake and binding within targeted disease micro-environments in patients: a new tool for translational medicine.了解药物在患者靶向疾病微环境中的摄取和结合：转化医学的新工具。
Clin Transl Med. 2012 May 31;1(1):8. doi: 10.1186/2001-1326-1-8.
2
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression.基于计算机断层扫描的生物标志物为 COPD 表型和疾病进展的诊断提供了独特的特征。
Nat Med. 2012 Nov;18(11):1711-5. doi: 10.1038/nm.2971. Epub 2012 Oct 7.
3
Statistical Methods for Tissue Array Images - Algorithmic Scoring and Co-training.组织阵列图像的统计方法——算法评分与协同训练
Ann Appl Stat. 2012 Sep;6(3):1280-1305. doi: 10.1214/12-aoas543.
4
Cancer bioinformatics: a new approach to systems clinical medicine.癌症生物信息学：系统临床医学的一种新方法。
BMC Bioinformatics. 2012 May 1;13:71. doi: 10.1186/1471-2105-13-71.
5
Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation.健康人群和慢性阻塞性肺疾病患者（伴有或不伴有急性加重）血浆炎症生物标志物的变化。
J Proteomics. 2012 Jun 6;75(10):2835-43. doi: 10.1016/j.jprot.2012.01.027. Epub 2012 Feb 10.
6
Cancer biomarkers: selecting the right drug for the right patient.癌症生物标志物：为合适的患者选择合适的药物。
Nat Rev Drug Discov. 2012 Feb 10;11(3):201-14. doi: 10.1038/nrd3651.
7
Role of clinical bioinformatics in the development of network-based Biomarkers.临床生物信息学在基于网络的生物标志物开发中的作用。
J Clin Bioinforma. 2011 Oct 24;1(1):28. doi: 10.1186/2043-9113-1-28.
8
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function.全基因组关联和大规模随访研究确定了 16 个新的影响肺功能的基因座。
Nat Genet. 2011 Sep 25;43(11):1082-90. doi: 10.1038/ng.941.
9
Clinical bioinformatics: a new emerging science.临床生物信息学：一门新兴科学。
J Clin Bioinforma. 2011 Jan 20;1(1):1. doi: 10.1186/2043-9113-1-1.
10
Selection of disease-specific biomarkers by integrating inflammatory mediators with clinical informatics in AECOPD patients: a preliminary study.通过将炎症介质与临床信息学相结合，选择 AECOPD 患者的疾病特异性生物标志物：一项初步研究。
J Cell Mol Med. 2012 Jun;16(6):1286-97. doi: 10.1111/j.1582-4934.2011.01416.x.
Zotero 插件